TNYANMSHealthcare·Biotechnology#336 in industry

Tenaya Therapeutics, Inc.

Reports in 17d· 2026-05-13

-0.3% · 90d

$0.70

+0.02 (+3.56%)

News

No News Yet

Press releases and SEC filings for TNYA will appear here as they are published.

Check back later for updates

Key Data

Market Cap$151.1M

Open$0.69

Prev Close$0.67

Day Range$0.68 – $0.72

52W Range$0.36 – $2.35

Volume3,142,621

P/E (TTM)—

EPS$-0.59

Dividend Yield—

Beta3.00

Price Target$9.00(+1192.9%)

Next Earnings2026-05-13(17d)

Analyst Ratings

Strong Buy8 analysts

Buy 8Hold 0Sell 0

About

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Healthcare · Biotechnology

70 employees

www.tenayatherapeutics.com